- Home
- HEPA
as 02-21-2025 4:00pm EST
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | EDISON |
| Market Cap: | 1.7M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 31.4M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.12 - $3.33 | Next Earning Date: | 04-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Hepion Pharmaceuticals Inc. News
HEPA Breaking Stock News: Dive into HEPA Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Hepion Pharmaceuticals Announces $9.0 Million Public Offering
GlobeNewswire
2 months ago
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
GlobeNewswire
3 months ago
Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group
GlobeNewswire
3 months ago
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
GlobeNewswire
3 months ago
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger
GlobeNewswire
6 months ago
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
GlobeNewswire
7 months ago
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
The Telegraph
8 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Compare HEPA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HEPA Hepion Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.